Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Embopag
- Development stage
- Unknown
- Lead developer
- Perini
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
Embopag is a small molecule thrombopoietin receptor (TPO-R) agonist marketed by Perin Healthcare for the treatment of thrombocytopenia. It acts as a mimetic of endogenous thrombopoietin by binding to the transmembrane domain of the TPO receptor (also known as MPL) on megakaryocytes and their progenitor cells. This binding activates intracellular signaling pathways, such as the JAK/STAT pathway, which promotes the proliferation and differentiation of megakaryocytes from bone marrow progenitor cells, ultimately increasing platelet production. Embopag is used in the management of conditions including chronic immune thrombocytopenia (ITP), severe aplastic anemia, and thrombocytopenia associated with chronic hepatitis C. It is an oral medication available in multiple strengths, including a 50 mg formulation.
- Brand names
- EmbopagEmbopag 50Embopag50Embopag-50
- Other names
- eltrombopag
02
Targets
TPOR (Thrombopoietin receptor)
Beyond the preview
Go deeper on Embopag.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Embopag.